Vaccinex, Inc. (OTC:VCNX) Financings
Financings
| Raise | Date |
|---|---|
| Revenue sharing agreement Announced: US$60M Buyers: Pepinemab Development Venture, LP ($60 million funding commitment in exchange for 50% of future economic proceeds from pepinemab neurological indications and 25% from other indications) Insiders: PDV is an investment entity established by FCMI, an existing Vaccinex investor; Albert Friedberg is Chairman of FCMI and of the Vaccinex Board. Use of proceeds: Advance development of pepinemab in an enlarged phase 2b clinical trial for Alzheimer's disease | Dec 23, 2025 |